Phase 3, multicenter, randomized, double-blind, parallel-group, placebo-controlled study to evaluate the efficacy and safety of certolizumab pegol (CZP) in subjects with adult onset active and progressive psoriatic arthritis (PsA).
Read more: http://www.clinicaltrials.gov/ct2/show/NCT01087788?cond=%22Arthritis%22&lup_s=07/14/2011&lup_d=30
